Avedro to Present Research on Proprietary Corneal Cross-Linking Technologies at 2019 ARVO Annual Meeting
22 Abril 2019 - 3:05PM
Avedro, Inc. (Nasdaq: AVDR) (Avedro), today announced that three
abstracts highlighting proprietary cross-linking technologies being
developed by Avedro have been accepted for poster presentations at
the upcoming 2019 Association for Research in Vision and
Ophthalmology (ARVO) Meeting being held April 28-May 2 in
Vancouver, BC. ARVO is the largest gathering of eye and vision
researchers in the world, attracting over 11,000 attendees from
more than 75 countries.
The presentations include data on technologies relating to
Avedro’s proprietary Epi-On (epithelial-on) and PiXL corneal
cross-linking procedures. Avedro’s Epi-On procedure is designed to
treat the cornea without the need to remove the epithelium and is
currently being studied in a U.S. pivotal Phase 3 clinical trial
for the treatment of progressive keratoconus, a debilitating and
typically progressive eye disease that, if left untreated, can lead
to loss of vision and even blindness. The PiXL procedure is in
development to non-invasively improve vision for patients with
presbyopia, the normal loss of near focusing ability that occurs
with age, which we estimate affects more than 50 million people in
the United States.
“Avedro is committed to developing important new technologies
for corneal cross-linking as we pursue next-generation solutions
for vision loss,” said Reza Zadno, PhD, President and Chief
Executive Officer of Avedro. “Our ability to conduct clinically
relevant research and collaborate with practitioners in the
development of new technologies shows our leadership in the field
of corneal cross-linking.”
The scientific poster presentations are scheduled as
follows:
Sunday, April 28
- 8:00-9:45 AM – Biomechanical Impact of Drug
Formulation, Supplemental Oxygen, and UV Delivery on Epi-On
CXL. Adler DC, Hill J, Liu C, Deardorff P, Raizman M,
Rajpal R. Poster #317-B0509.
- 8:00-9:45 AM – Stromal Oxygen Dynamics During
High-Irradiance Epi-On Corneal Crosslinking. Hill J, Liu
C, Deardorff P, Thompson V, Gore D, Adler DC. Poster #325-B0517.
- 8:00-9:45 AM – Impact of Eye Motion and Active vs.
Passive Eye Tracking on Refractive Crosslinking. Usher D,
Mukherjee A, Smirnov M, Hill J, Eddington W, Liu C, Adler DC.
Poster #327-B0519.
About Avedro, Inc.
Avedro is a leading commercial-stage ophthalmic medical
technology company focused on treating corneal ectatic disorders
and improving vision to reduce dependency on eyeglasses or contact
lenses. Avedro’s proprietary Avedro Corneal Remodeling Platform is
designed to strengthen, stabilize and reshape the cornea utilizing
corneal cross-linking in minimally invasive and non-invasive
outpatient procedures to treat corneal ectatic disorders and
correct refractive conditions. The Avedro Corneal Remodeling
Platform is comprised of Avedro’s KXL and Mosaic systems, each of
which delivers ultraviolet A light, and a suite of proprietary
single-use riboflavin drug formulations, which, when applied
together to the cornea, induce a biochemical reaction called
corneal collagen cross-linking.
Avedro Contact: |
Investor Contact: |
David Iannetta |
Greg Chodaczek or Lynn Lewis |
Phone: 781-768-3400 |
Phone: 646-924-1769 |
info@avedro.com |
investors@avedro.com |
Avedro (NASDAQ:AVDR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Avedro (NASDAQ:AVDR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Avedro Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias